A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans

被引:51
作者
Delacher, S
Derendorf, H
Hollenstein, U
Brunner, M
Joukhadar, C
Hofmann, S
Georgopoulos, A
Eichler, HG
Müller, M
机构
[1] Univ Vienna, Sch Med, Allgemeines Krankenhaus Wien, Div Clin Pharmacokinet,Dept Clin Pharmacol, A-1090 Vienna, Austria
[2] Univ Vienna, Sch Med, Allgemeines Krankenhaus Wien, Div Infect Dis & Chemotherapy,Dept Internal Med 1, A-1090 Vienna, Austria
[3] Univ Vienna, Sch Med, Allgemeines Krankenhaus Wien, Div Angiol,Dept Internal Med 2, A-1090 Vienna, Austria
[4] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
关键词
D O I
10.1093/jac/46.5.733
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We describe a new approach to quantify in vivo anti-infective activity by simulating effect site pharmacokinetics of antibiotics in vitro. This approach is based on (i) the in vivo measurement of interstitial drug pharmacokinetics (PK) at the target site and (ii) a subsequent pharmacodynamic (PD) simulation of the time versus drug concentration profile in an in vitro setting. To demonstrate the feasibility of this approach, individual time-concentration profiles of ciprofloxacin were measured in the interstitial space fluid of eight healthy volunteers by microdialysis following iv administration of 200 mg. Thereafter, different isolates of Pseudomonas aeruginosa were exposed in vitro to the interstitial ciprofloxacin concentration profile obtained from in vivo experiments. This led to a 1- to 3-log(10) decrease in the number of viable organisms after 8 h. Significant correlations were observed between the maximal bactericidal effect and several PK surrogate parameters, notably the AUC/MIC ratio (P = 0.0005), the C-max/MIC ratio (P = 0.006) and the time > MIC (P = 0.02). Furthermore, the data were analysed with an integrated PK-PD model allowing a much more detailed evaluation of the data than using MIG. The model employed an E-max relationship to link unbound ciprofloxacin concentration to bacterial kill rate. In conclusion, our experiments show that therapeutic success and failure in antimicrobial therapy may be explained by pharmacokinetic variability at the target site. Therefore, the in vivo PK-in vitro PD approach presented in our study may provide valuable guidance for drug and dose selection of antimicrobial agents.
引用
收藏
页码:733 / 739
页数:7
相关论文
共 25 条
[1]   Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans [J].
Bowker, KE ;
Holt, HA ;
Lewis, RJ ;
Reeves, DS ;
MacGowan, AP .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :461-467
[2]   Surgery and intensive care procedures affect the target site distribution of piperacillin [J].
Brunner, M ;
Pernerstorfer, T ;
Mayer, BX ;
Eichler, HG ;
Müller, M .
CRITICAL CARE MEDICINE, 2000, 28 (06) :1754-1759
[3]   Distribution and antimicrobial activity of ciprofloxacin in human soft tissues [J].
Brunner, M ;
Hollenstein, U ;
Delacher, S ;
Jäger, D ;
Schmid, R ;
Lackner, E ;
Georgopoulos, A ;
Eichler, HG ;
Müller, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1307-1309
[4]   Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis [J].
Dalla Costa, T ;
Nolting, A ;
Kovar, A ;
Derendorf, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (06) :769-778
[5]  
DallaCosta T, 1997, INT J CLIN PHARM TH, V35, P426
[6]   THE PENETRATION OF CIPROFLOXACIN INTO BRONCHIAL-MUCOSA, LUNG PARENCHYMA, AND PLEURAL TISSUE AFTER INTRAVENOUS ADMINISTRATION [J].
DAN, M ;
TOROSSIAN, K ;
WEISSBERG, D ;
KITZES, R .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (01) :101-102
[7]  
DUDLEY MN, 1987, AM J MED, V82, P363
[8]   MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model [J].
Firsov, AA ;
Vostrov, SN ;
Shevchenko, AA ;
Zinner, SH ;
Cornaglia, G ;
Portnoy, YA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2848-2852
[9]   A new approach to in vitro comparisons of antibiotics in dynamic models: Equivalent area under the Curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities [J].
Firsov, AA ;
Vostrov, SN ;
Shevchenko, AA ;
Portnoy, YA ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2841-2847
[10]   Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: New insight into a widely used concept [J].
Firsov, AA ;
Shevchenko, AA ;
Vostrov, SN ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :659-665